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ARTICLE
Natural Gene-Expression Variation in Down Syndrome Modulates
the Outcome of Gene-Dosage Imbalance
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Mauro Delorenzi, Corinne Gehrig, Patrick Descombes, Stephanie Sherman, Franca Dagna Bricarelli,
Chiara Baldo, Antonio Novelli, Bruno Dallapiccola, and Stylianos E. Antonarakis
Down syndrome (DS) is characterized by extensive phenotypic variability, with most traits occurring in only a fraction
of affected individuals. Substantial gene-expression variation is present among unaffected individuals, and this variation
has a strong genetic component. Since DS is caused by genomic-dosage imbalance, we hypothesize that gene-expression
variation of human chromosome 21 (HSA21) genes in individuals with DS has an impact on the phenotypic variability
among affected individuals. We studied gene-expression variation in 14 lymphoblastoid and 17 ﬁbroblast cell lines from
individuals with DS and an equal number of controls. Gene expression was assayed using quantitative real-time poly-
merase chain reaction on 100 and 106 HSA21 genes and 23 and 26 non-HSA21 genes in lymphoblastoid and ﬁbroblast
cell lines, respectively. Surprisingly, only 39% and 62% of HSA21 genes in lymphoblastoid and ﬁbroblast cells, respectively,
showed a statistically signiﬁcant difference between DS and normal samples, although the average up-regulation of
HSA21 genes was close to the expected 1.5-fold in both cell types. Gene-expression variation in DS and normal samples
was evaluated using the Kolmogorov-Smirnov test. According to the degree of overlap in expression levels, we classiﬁed
all genes into 3 groups: (A) nonoverlapping, (B) partially overlapping, and (C) extensively overlapping expression dis-
tributions between normal and DS samples. We hypothesize that, in each cell type, group A genes are the most dosage
sensitive and are most likely involved in the constant DS traits, group B genes might be involved in variable DS traits,
and group C genes are not dosage sensitive and are least likely to participate in DS pathological phenotypes. This study
provides the ﬁrst extensive data set on HSA21 gene-expression variation in DS and underscores its role in modulating
the outcome of gene-dosage imbalance.
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The clinical presentation of Down syndrome (DS) or tri-
somy 21 (MIM 190685) is complex and highly variable.1
Cognitive impairment, muscle hypotonia at birth, and
dysmorphic features occur to some extent in all affected
individuals. In contrast, the majority of the other asso-
ciated traits are present in only a fraction of individuals
with trisomy 21. In addition, the severity of many phe-
notypic traits varies greatly.2
Theoretically, the supernumerary copy of human chro-
mosome 21 (HSA21) is expected to result in a 50% increase
in the level of transcripts of all genes mapping to HSA21.
However, it has been recently observed that there is not
always a direct correlation between genomic imbalance
(deletion or duplication) and transcript level of genes
within the aneuploid segment, suggesting that complex
molecular mechanisms regulate RNA transcript levels.3–5
An additional level of complexity comes from the recent
observations of extensive gene-expression variation
among unaffected individuals and that a signiﬁcant frac-
tion of this variation is controlled by genetic variation,
either in cis or trans to the individual gene.6–8 In a previous
study, we showed, by quantitative PCR, that there is also
extensive expression variation for HSA21 genes, with
some genes varying up to 40-fold among individuals.9,10
These ﬁndings may have direct implications for the phe-
notypic variability of DS and underlie the need to re-eval-
uate our models of dosage imbalance and how they relate
to human disorders.
To date, very little is known about the genes and path-
ways involved in DS pathology, although recently the in-
volvement of the nuclear factor of activated T cells
(NFAT)11 pathway and Sonic hedgehog12 pathwayhas been
postulated. Several previous genomewide expression stud-
ies analyzed the pattern and extent of gene expression
dysregulation in human trisomy 21 and its mousemodels,
to identify candidate genes responsible for DS pheno-
types.13–19 All these studies detected the expected up-reg-
ulation of a fraction of HSA21 transcripts. However, small
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Table 1. Characteristics of Cell Lines
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 2. TaqMan Assays
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
sample sizes and limitations inherent to microarray tech-
nology have precluded detailed analysis of interindividual
variation.
We hypothesize that natural gene-expression variation
of HSA21 genes in individuals with trisomy 21 contributes
to the phenotypic variability in DS. We expect that, for a
fraction of genes, there is a degree of overlap of expression
levels between individuals with DS and unaffected indi-
viduals, whereas, for other genes, the distributions of ex-
pression levels are distinct. Those genes with expression
overlap are thus candidates for the variable phenotypes
of DS, likely the result of a threshold effect.20 In contrast,
genes with distinct distributions are candidates for the
constant features of DS.
To classify transcripts according to the overlap of ex-
pression levels between DS and normal samples and to
determine the impact of natural gene-expressionvariation
in the context of aneuploidies, we studied gene-expression
variation by quantitative real-time PCR. We analyzed 14
lymphoblastoid cell lines (LCLs) and 17 ﬁbroblast cell lines
from individuals with DS and an equal number of
matched controls and assayed HSA21 annotated genes
that are expressed in LCLs and ﬁbroblasts.
Material and Methods
Lymphoblastoid and Fibroblast Cell Culture
Epstein Barr virus (EBV)–transformed LCLs and ﬁbroblast cell
lines were obtained from Coriell cell repositories (Coriell Institute
for Medical Research) (14 LCLs and 28 ﬁbroblasts), Galliera Ge-
netic Bank of Genoa (4 LCLs and 5 ﬁbroblasts), Emory University
School of Medicine in Atlanta (8 LCLs), and CSS-Mendel Institute
in Rome (3 LCLs). All cell lines were assessed for full trisomy by
karyotyping. LCLs and ﬁbroblasts were collected from different
individuals, and the control samples for both cell lines were
matched for sex and ethnicity. Age was matched for ﬁbroblasts,
but, for LCLs, individuals with DS were, on average, younger than
control individuals (table 1). Informed consent was obtained for
all human samples, and the study was approved by the ethics
committee of the Geneva University Hospital.
LCLs were grown in RPMI 1640 with Glutamax I medium (In-
vitrogen) supplemented with 10% fetal calf serum and 1% mix
of penicillin, fungizone, and streptomycin (Invitrogen). Fibro-
blasts were cultured in Dulbecco’s modiﬁed Eagle medium with
Glutamax I plus Na pyruvate (Invitrogen) supplemented with the
same antibiotic mix.
The cell lines were treated with a standardized procedure, to
minimize environmental variation. Cell lines were harvested at
a density of cells/ml or cells/dish and6 60.6–1# 10 6.5–10# 10
at least 80% viability. LCLs and ﬁbroblasts (after trypsinization)
were spun for 5 min at 1,000 g, and the resulting pellets were
rinsedwith PBS andwere lysedwith 1ml lysis solution containing
b-mercaptoethanol (RNeasy kit [Qiagen]). Cell pellets were stored
at 80C.
Total RNA was extracted using the RNeasy kit (Qiagen), in-
cluding the DNAse step in accordance with the manufacturer’s
protocol. RNA samples were then quantiﬁed with NanoDrop
(NanoDrop Technologies) and were analyzed for quality control
on a 2100 BioAnalyzer by use of the RNA 6000 Nano LabChip
(Agilent).
cDNAs were synthesized from total RNA by use of SuperScriptII
reverse transcriptase (Invitrogen) and a poly d(T) primer. For each
cell line, 10.5 mg of total RNA was used to perform three reverse-
transcriptase reactions, and the resulting cDNA was diluted 1:14
before PCR.
Gene Selection
On the basis of a combination of the Hattori et al.21 and Ensembl
annotations, we initially considered 258 genes on HSA21. We
excluded from our analysis (i) pseudogenes, (ii) gene predictions
supported by spliced ESTs but not complete mRNAs, (iii) genes
supported only by ab initio predictions, (iv) single-exon genes,
and (v) two genes for which it was not possible to design assays
by use of our default parameters. We also excluded 27 genes from
the KRTRAP cluster that are almost exclusively expressed in hair
root and for which it was impossible to design speciﬁc primer-
probe sets. This resulted in a total of 178 genes for which we
designed a TaqMan assay.
Primers and probes were selected using Primer Express version
2.0 (Applied Biosystems) with default parameters. Assay efﬁcien-
cies were calculated using ﬁve fourfold serial dilutions of a pool
of human brain, liver, and testis cDNAs, as described elsewhere.3,9
When transcripts were not expressed in brain, liver, and testis,
efﬁciencies were tested in a pool of LCLs and ﬁbroblasts. Of the
178 genes, 43 did not pass our efﬁciency criteria threshold (0.95–
1.05) and were excluded from further analysis. The remaining
135 genes were tested in a pool of ﬁve LCL cDNAs and ﬁve ﬁ-
broblast cDNAs, to determine their expression in these cell types.
A total of 117 and 114 genes were expressed in LCLs and ﬁbro-
blasts, respectively, and were retained for subsequent analysis.
In addition, we designed assays for 30 non-HSA21 genes.
Among these, ﬁve genes for LCLs and four genes for ﬁbroblasts
were selected for normalization, and the remaining genes were
used as additional controls. Selection of normalization genes was
performed with GeNorm software.22 A list of all the assays used
is provided in table 2.
Quantitative Real-Time PCR
Real-time quantitative PCR was performed as described else-
where,3,9 with minor modiﬁcations. Each gene was ampliﬁed in
six replicates per individual. The assays for each individual were
performed in -well plates. To assess possible technical er-3# 384
rors generated by interplate variations in ampliﬁcation, we placed
three control genes (AGPAT1, EEF1A1, and B2M) in each plate.
We performed different normalization procedures, using either
genes in the ﬁrst plate or genes present in each plate. Different
normalization methods were highly correlated (Spearman’s rank
correlation ; ), suggesting that inter-16rp 0.8955 Pp 2.2# 10
plate variation gives a negligible contribution to the expression
variability observed.
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Table 3. Average Up-Regulation and
Associated P Values of Genes in Trisomy
Samples
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Moreover, on the basis of two previous studies, we have esti-
mated that the variance of gene-expression levels due to culture
conditions is extremely low. For example, Merla et al.4 established
six independent LCLs for the same individual and compared ex-
pression levels for 25HSA21 genes. For all genes, correlationswere
between 0.8 and 0.92. In addition, LCLs from the HapMap col-
lection were cultured, and RNA was extracted from two different
laboratories; the gene-expression levels showed very high overall
correlation, suggesting that the uncontrolled culturing param-
eters did not signiﬁcantly contribute to the measured gene-
expression variation.10,23 In total, 53,346 quantitative real-time
PCR reactions were performed.
Data Analysis
Raw cycle threshold (CT) values were obtained using SDS 2.1 soft-
ware (Applied Biosystems). Baseline values were automaticallyde-
termined, and threshold values were manually adjusted for each
gene. Values with a deviation of 0.25 CT with respect to the me-
dian (which corresponds to the 99% CI) were considered outliers
and were excluded.
Transcripts that ampliﬁed with a CT value 137.9 and in fewer
than seven individuals per sample set were not included in the
analysis. Each gene was rescaled using the mean expression value
of control individuals, to give a relative normalized value. Data
handling and normalizations were performed using Excel (Mi-
crosoft Corporation) and R (The R Project for Statistical Com-
puting) software.
To assess the differences in gene-expression values between in-
dividuals with DS and unaffected individuals in LCLs and ﬁbro-
blast cell lines, we performed the Kruskal-Wallis (KW) test. P
values were corrected for multiple testing by use of the false-
discovery rate (FDR) method of Benjamini and Hochberg.24 We
applied a conservative signiﬁcance threshold of 1% FDR.
As an alternative method to compare the distributions of the
expression values between individuals with DS and unaffected
individuals and to compare their degree of overlap, we used the
Kolmogorov-Smirnov (KS) test. The KW and KS tests were im-
plemented using Minitab and R software, respectively.
To determine whether there is contiguous gene region on
HSA21 that signiﬁcantly departs from the expected 1.5-fold gene-
expression dysregulation in DS, we performed a sliding-window
analysis. We used the averaged ratio of expression in DS samples
versus in euploid samples (DS:euploid) or the log P value (from
the KW test) in a ﬁxed window of four genes as the test statistic
and assessed signiﬁcance by a permutation test randomizing the
order of the HSA21 genes.
Pathway analysis was performed using IPA software (Ingenuity
System). In brief, gene lists were created using the D value clas-
siﬁcation from the KS test, to identify potential enrichment for
certain functional categories.
Results
HSA21 Gene Expression in LCLs and Fibroblasts
To analyze HSA21 gene-expression differences between in-
dividuals with DS and euploid individuals, we designed
and tested 178 TaqMan assays (see the “Material and
Methods” section for the criteria used for selection). A
total of 135 assays met our efﬁciency (E) criteria of
in a pool of human brain, liver, and testis0.95 ! E ! 1.05
RNA; these assays constitute our HSA21 TaqMan set (ﬁg.
1A).
To select appropriate gene sets to study in each cell type,
we tested the HSA21 TaqMan set in RNAs from a pool of
ﬁve LCLs and ﬁve ﬁbroblast cell lines. We used CT of 37.9
as the threshold for declaring a gene expressed, and, on
the basis of these criteria, we selected 117 and 114 genes
for LCLs and ﬁbroblasts, respectively (ﬁg. 1A). In addition,
30 non-HSA21 genes were incorporated into the analysis
(table 2).
HSA21 expression levels were measured in 29 LCLs (14
normal and 15 trisomy 21) and 33 ﬁbroblasts (16 normal
and 17 trisomy 21). Genes that were not detected in at
least seven individuals per group were eliminated, leaving
a total of 128 LCL-expressed genes (100 on HSA21) and
136 ﬁbroblast-expressed genes (106 on HSA21) for the ﬁ-
nal analyses (table 2).
HSA21 Gene Overexpression in Trisomy 21
Comparison of expression levels between individualswith
trisomy 21 and euploid individuals revealed a general
overexpression of HSA21 transcripts in affected individ-
uals compared with unaffected individuals, both in LCLs
and in ﬁbroblasts ( for LCLs and7Pp 3.783# 10 Pp
for ﬁbroblasts, by KW test). We observed that162.2# 10
39% (39/100) of HSA21 transcripts in LCLs and 62% (66/
106) in ﬁbroblasts showed a signiﬁcant expression differ-
ence between the DS and euploid samples. The signiﬁ-
cance threshold was set at .01 after correction for multiple
testing by use of the Benjamini-Hochberg FDR.24 The av-
erage up-regulation ratio (DS:euploid) was 1.44 in LCLs
and 1.67 in ﬁbroblasts; these values are similar to the ex-
pected up-regulation of gene expression of 1.5-fold in tri-
somy 21 (ﬁg.1B and table 3). None of the genes tested in
both cell types showed signiﬁcant down-regulation in DS
samples compared with in normal samples. These results
are consistent with previously published data showing an
overall up-regulation of HSA21 genes in individuals with
DS and in trisomy 21 mouse models.5,13,15,17,18,25,26
Examples of some of the statistically signiﬁcantly ov-
erexpressed genes in LCLs (with their corresponding fold
overexpression and corrected P values formultiple testing)
are GABPA (1.48-fold; ), PFKL (1.57-fold;Pp .0006 Pp
), ITGB2 (1.65-fold; ), and TMPRSS3 (8.1-.0006 Pp .0006
fold; ). For ﬁbroblasts, examples include U2AF1Pp .0006
(1.76-fold; ), USP16 (1.77-fold;5Pp 4.81# 10 Pp
), DONSON (2.24-fold; ), and5 54.81# 10 Pp 4.81# 10
GART (1.54-fold; ).5Pp 4.81# 10
As an additional control, we assessed whether transcript
Figure 1. A, Representation of HSA21 genes analyzed. In the ﬁrst column, dark pink indicates assays with efﬁciency (E) 0.95–1.05,
light pink indicates assays with efﬁciency !0.95 (not used in this study), and white indicates assays not designed (see selection criteria
in the “Material and Methods” section). The different shades of blue represent the average level of expression for each gene in LCLs
and ﬁbroblasts; genes with no expression data available are in white. B, Histograms of average ratio of expression in DS versus in
euploid samples (DS/Eu) for HSA21 genes (gray) and non-HSA21 genes (yellow) in LCLs (left panel) and ﬁbroblasts (right panel). C,
Average DS/Eu expression ratios of 100 HSA21 genes in LCLs (upper panel) and of 106 HSA21 genes in ﬁbroblasts (lower panel). Each
dot corresponds to the average of normalized expression values for HSA21 genes according to their order along the chromosome. The
range of P values is shown; red indicates lower P values, and black indicates higher P values.
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up-regulation speciﬁcally involved HSA21 genes. Wemea-
sured the expression level of 23 genes expressed in LCLs
and 26 genes expressed in ﬁbroblasts localized outside
HSA21. The gene-expression ratio (DS:euploid) for these
non-HSA21 transcripts was 1.02 in LCLs and 1.14 in ﬁ-
broblasts, which was signiﬁcantly different from that for
HSA21 genes in the two cell types ( for6Pp 1.305# 10
LCLs and for ﬁbroblasts) (ﬁg. 1B). Although92.865# 10
non-HSA21 genes did not show a general up-regulation,
WBSCR18 (HSA7) was signiﬁcantly upregulated in DS ﬁ-
broblast samples compared with in normal ﬁbroblast sam-
ples (corrected , by KW test) (table 3).Pp .00366
To test whether there were any regional patterns of ex-
pression dysregulation, we performed a sliding-window
permutation test of the analyzed HSA21 genes. Permuta-
tion analysis did not reveal statistically signiﬁcant evi-
dence of a cluster of contiguous genes showing locally
higher overexpression or underexpression among the
studied set of HSA21 genes. This suggests that the tran-
scriptional dysregulation of HSA21 genes in trisomy 21 is
uniformly spread along the chromosome (ﬁg. 1C) and is
not preferentially located in certain areas, which is con-
sistent with previous reports.16
One interesting outlier is TMPRSS3, for which we found
an average DS:euploid ratio of 8.1 (ﬁg. 1C), which is much
higher than would be expected from the genomic imbal-
ance alone. This suggests that additional mechanisms,
such as positive feedback loops, might be operating for
this gene. TMPRSS3 was not expressed in ﬁbroblasts, pre-
cluding a comparison between the two cell types.
Gene-Expression Variation in DS and Normal Samples
Since we found that a substantial fraction of HSA21 genes
are not signiﬁcantly overexpressed in the trisomy 21 pop-
ulation in the two cell types analyzed, we surmised that
interindividual differences in the levels of expression
could partly explain this observation. To evaluate the ex-
tent of gene-expression variation among individuals, we
measured the coefﬁcient of variation (CV) of the nor-
malized expression values for each gene in both cell types.
We observed a wide distribution of CVs, in the range
0.14–1.29 in LCLs and 0.14–1.49 in ﬁbroblasts, with me-
dians of 0.31 and 0.34, respectively. Within each cell type,
the CVs were not signiﬁcantly different between unaf-
fected individuals and individuals with DS ( forPp .052
LCLs and for ﬁbroblasts). For some genes (e.g.,Pp .084
PWP2), the CV is low in both cell types (0.17 and 0.19 in
LCLs and ﬁbroblasts, respectively), suggesting that the ex-
pression of the gene is tightly regulated, whereas, for other
genes (e.g., KCNJ15), the CV is approximately seven times
higher (1.03 and 1.25), suggesting a less controlled tran-
scriptional regulation for the gene in the two cell types
analyzed (ﬁg. 2A).
The distributions of the CVs were not signiﬁcantly dif-
ferent between the two cell types ( , by KW test),Pp .146
and, interestingly, we observed a signiﬁcant correlation in
the levels of gene-expression variation between ﬁbroblasts
and LCLs (Spearman’s ; ), sug-9rp 0.58 Pp 1.717# 10
gesting that a majority of the genes show a similar pattern
of expression variation across cell types (ﬁg. 2B), which is
consistent with previous observations.3
To determine whether the degree of interindividual
gene-expression variation could partly explain why cer-
tain HSA21 genes are not signiﬁcantly overexpressed in
the DS samples, we performed a regression analysis for all
genes, taking the CV as the “predictor” and the log P
value of the expression difference (euploid vs. DS) as the
“response.” The results of the regression analysis were
highly signiﬁcant for both cell types ( for12Pp 1.0# 10
LCLs and for ﬁbroblasts), showing that,16Pp 2.3# 10
as CV increases, the P values tend to increase (with R2
values of 0.42 and 0.58 in LCLs and ﬁbroblasts, respec-
tively) (ﬁg. 2C). Hence, the degree of gene-expression var-
iation contributes, to a large extent, to the determination
of whether HSA21 genes are signiﬁcantly overexpressed
in the DS samples.
Estimating the Degree of Overlap of Gene Expression
between DS and Normal Samples
Given the considerable gene-expression variation ob-
served for many genes (ﬁg. 3), we decided to approach
the problem of overexpression, not only in terms of the
average expression dysregulation in DS samples compared
with in normal samples, but also in terms of the amount
of overlap in the distribution of expression values between
the two groups. For this purpose, we used the KS test,
which measures the distance between empirical cumula-
tive distributions of expression levels in DS samples com-
pared with normal samples for each gene.
A D value and an associated P value are assigned to each
gene according to their degree of overlap between the two
distributions of expression values (in DS and normal sam-
ples). The D values range from 0 (i.e., no difference be-
tween the two distributions) to 1 (i.e., nonoverlapping
distributions).
Using this approach, we classiﬁed all HSA21 genes into
three groups. Group A had D values of 0.8–1, correspond-
ing to genes with little or no overlap in the distribution
between DS and normal samples (ﬁg. 4). This group of
genes—including, for example, IFNAR2, GABPA, and
SUMO3—are highly dosage sensitive and are the most eas-
ily identiﬁable as upregulated by use of microarray anal-
ysis.19 Group B had D values of 0.5–0.8, corresponding to
genes with partially overlapping distributions (for exam-
ple, USP25, DSCR2, PIGP, andHUNK); for these genes, only
a fraction of trisomy 21 samples show expression values
above the distribution of the normal (euploid) samples.
Group C had D values !0.5, corresponding to genes that
are effectively dosage insensitive, partly as a result of the
substantial gene-expression variation in the population.
For these genes, we observed an extensive expression over-
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Figure 2. A, Examples of box plots of gene-expression values for two genes, PWP2 and KCNJ15. The Y-axis is normalized expression
values; the X-axis is the 62 samples, grouped by cell type (LN p normal LCLs; LD p DS LCLs; FN p normal ﬁbroblasts; FD p DS
ﬁbroblasts). The left panel shows an example of a gene with low expression variance (!0.20), and the right panel shows a gene with
high expression variance (11). B, Distribution of CV of gene expression in LCLs (red) (median 0.31) and ﬁbroblasts (green) (median
0.34). C, Regression curve of CVs versus the logP of the KW test in LCLs (red) and ﬁbroblasts (green), showing an inverse correlation
between the CV and the logP of the KW test.
lap between the two groups. Examples in this group in-
clude JAM2, PCNT, BAGE4, and CBS.
Sixty (60%) of the 100 HSA21 genes studied in LCLs and
73 (69%) of the 106 HSA21 genes studied in ﬁbroblasts
were in groups A and B (D values 10.5; P values !.05),
showing that the majority of HSA21 genes are sensitive
to the dosage imbalance, even in the presence of gene-
expression variation (ﬁg. 4). Interestingly, the number of
group A genes is signiﬁcantly higher in ﬁbroblasts than
in LCLs (ﬁg. 4A). This may be because of the EBV trans-
formation process, which may cause a transcriptional pro-
gram in LCLs altered from that in ﬁbroblasts that are pri-
mary cell lines.27
To systematically compare the degree of overlap be-
tween the two cell types studied, we focused on 91 genes
that are commonly expressed in LCLs and ﬁbroblasts. In-
formation about the extent of overlap for genes that were
speciﬁcally expressed either in LCLs or in ﬁbroblasts is
summarized in ﬁgure 5. Overall, there was a high corre-
lation of D values between the two cell types ( ;rp 0.518
). In addition, 76% of genes are in the7Pp 1.452# 10
same or similar (A or B) gene group in both cell types (ﬁg.
4B), showing that a substantial proportion of genes display
a similar degree of dosage sensitivity in both cell types.
We performed a pathway analysis to determinewhether
the different groups of genes (A, B, and C) were enriched
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Figure 3. Box plots of normalized expression levels of 91 HSA21 genes expressed in both LCLs and ﬁbroblasts. The Y-axis is normalized
expression values, with data points in the range 0–3.5; the X-axis is the four cell/genotype groups (LNp normal LCLs; LDp DS LCLs;
FN p normal ﬁbroblasts; FD p DS ﬁbroblasts). Each panel represents a gene (shown on top).
for involvement in particular pathways or biological pro-
cesses. Interestingly, genes in group A and/or B, both in
LCLs and ﬁbroblasts, showed an enrichment in the inter-
feron-IL10RB signaling pathway (P range –51.79# 10
). This network includes IFNAR1, IFNAR2,21.52# 10
IL10RB, and IFNGR2, genes known to cluster in ∼250 kb
on 21q22.11, known to be conserved down to chicken as
a syntenic block.28
Discussion
DS is considered a disorder of gene-expression imbalance
in which allelic differences are likely to be important de-
terminants of the phenotypic variability. Several recent
studies, mainly using LCLs and array-based transcriptome
analyses, concluded that there is substantial gene-expres-
sion variation in unaffected individuals.7,29,30 In addition,
a considerable fraction of this normal gene-expressionvar-
iation is genetically determined.8–10 Thus, a likely molec-
ular mechanism for the variability of phenotypic mani-
festations of trisomy 21 is a threshold effect of expression
of HSA21 genes that show variable levels of expression in
the population.20
In this study, we have looked at HSA21 gene overex-
pression in trisomy 21 in the context of natural gene-
expression variation. This enabled us to determine genes
for which the additional copy results in signiﬁcant over-
expression in individuals with DS (dosage-sensitive genes)
and genes for which the additional copy does not result
in overexpression outside of the range in unaffected in-
dividuals (dosage-insensitive genes).
We measured HSA21 gene-expression levels, using two
different cell types from samples originating from differ-
ent DS-affected individuals (15 LCLs and 17 ﬁbroblasts)
and matched controls (14 LCLs and 16 ﬁbroblasts). In to-
tal, we measured gene-expression levels for 100 and 106
expressed HSA21 genes in the two cell types.
On average, the steady-state RNA levels of genes on
HSA21 in trisomy 21 is expected to be 1.5-fold that in
unaffected individuals. This is close to what we observed
here: the mean overexpression of HSA21 genes was 1.44-
fold and 1.67-fold in LCLs and ﬁbroblasts, respectively.
Interestingly, however, only 39% and 62% of genes in the
two cell types were found to be signiﬁcantly overexpressed
( , by KW test, after correction for multiple testing)P ! .01
in the trisomy 21 samples compared with in the euploid
samples. Several mechanisms could explain this apparent
discordance between the genomic dosage imbalance and
the expression levels, such as negative feedback, epige-
netic dosage compensation, or gene-expression variation.
Because we and others previously reported extensive levels
of interindividual gene-expression variation of HSA21
genes,9,30,31 we have assessed the relationship between
HSA21 gene overexpression and natural expression vari-
ation (measured as the CV). We found a wide distribution
of CVs for HSA21 gene expression in both cell types (range
0.14–11), which is consistent with previously published
data,3,16 with ∼75% of genes having a CV !0.5. Regression
analysis clearly showed that genes with higher CV tended
to be less overexpressed in DS samples, and vice versa,
suggesting that gene-expression variation explains, to a
large extent, why many HSA21 genes are not signiﬁcantly
upregulated in trisomy 21.
One major objective of this study was to categorize
HSA21 genes according to the degree of overlap of gene
expression between trisomy 21 and euploid samples, be-
cause we hypothesized that a threshold effect of gene ex-
pression might partially explain the phenotypic variation
among individuals with DS. We classiﬁed the genes tested
into three groups, using the D statistic of the KS test that
measures the degree of overlap. Genes in group A have
minimal expression overlap between DS and normal sam-
ples and are candidates for involvement in DS phenotypes
that are present in all affected individuals, such as mental
retardation, muscle hypotonia, and Alzheimer disease.
This is because the expression levels of this gene group in
DS samples are consistently higher than those in control
samples. Genes in this group (in both cell types tested)
include PRMT2, involved in nuclear factor kB signaling
and apoptosis32; SUMO3, encoding a protein involved in
posttranslational modiﬁcation of proteins (including
p53), many of which are linked to senescence, DNA repair,
and apoptosis33; and MCM3AP, involved in the regulation
of DNA replication.34 In addition, four genes involved in
the interferon-IL10RB signaling pathway (IFNAR1, IFNAR2,
IL10RB, and IFNGR2), which have been kept in a single
syntenic block throughout vertebrate evolution, are in
group A in ﬁbroblasts.27
Group B genes have partially overlapping expression
distributions between DS and normal samples and are
likely to be involved in the variable features of DS. The
working hypothesis for these genes is that, if the level of
expression reaches a given threshold (that must be above
the highest value observed for unaffected individuals),
then the probability of the manifestation of a given phe-
notype is very high. This group includes a substantial
number of genes (about half in LCLs and one-third in
ﬁbroblasts), such as SON, encoding a DNA-bindingprotein
likely to be involved in cellular defense against hepati-
tis B virus35; ETS2, an oncogene involved in the normal
embryonic anteroposterior axis and skeletal develop-
ment36,37; and PDXK, which is involved in vitamin B6
metabolism.38,39
Genes in group C show extensive overlap in the distri-
Figure 4. A, Pie charts of D values between the three groups of genes A, B, and C in LCLs and ﬁbroblasts. Group A contains genes
with minimal expression overlap between DS and normal samples, group B contains genes with partial overlap, and group C contains
genes that show extensive overlap of expression values between DS and control samples. B, Classiﬁcation of 91 HSA21 genes on the
basis of their expression overlap between trisomy 21 and the euploid samples in the two cell types (LCLs and ﬁbroblasts). Each gene
is grouped into one of three categories of similarity—“very similar,” “analogous,” and “very different”—on the basis of the similarity
of D values between the two cell types.
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Figure 5. Box plots of normalized expression levels of 9 HSA21
genes expressed only in LCLs and of 15 HSA21 genes expressed
only in ﬁbroblasts. The legend is available in its entirety in the
online edition of The American Journal of Human Genetics.
bution of expression values between DS and control sam-
ples and are effectively dosage insensitive in the cell types
analyzed. Examples include ADARB1, encoding an RNA-
editing enzyme40; JAM2, encoding an adhesion molecule
involved in the formation of tight junctions and trans-
endothelial migration41; and ICOSLG, involved in T-cell
regulation and acute immunoresponse.42 Although genes
in this category are less likely to be involved in DS phe-
notypes, it would be naive to exclude completely their
involvement in DS, since some of these may have regu-
latory mechanisms that are speciﬁc to cell type or devel-
opmental stage. Clear examples of genes that are in group
C in the two cell types studied but are known to contribute
to DS features include APP, which has been shown to be
dosage sensitive in the brain,43 with overexpression re-
sulting in early-onset Alzheimer disease, and CBS, which
alters homocysteine metabolism in plasma of individuals
with DS.44 This emphasizes the need to perform similar
studies in additional cell types and tissues at different de-
velopmental stages. An additional limitation of this study
is that not all known spliced isoforms of genes have been
examined; it is possible that speciﬁc isoforms could be
categorized in different expression-overlap groups.
Comparison of gene-expression overlap betweenDS and
control samples (D values from KS test) for the 91 genes
expressed in the two cell types revealed a signiﬁcant level
of correlation for amajority of genes (76%). The remaining
genes, on the other hand, showed cell type–speciﬁc reg-
ulation—for example, PKNOX1, encoding a homeobox
transcription factor involved in development,45 showed
consistent levels of overexpression in ﬁbroblasts but not
in LCLs, and the opposite was true for ITGB2, which is
involved in cell adhesion and cell-surface–mediated
signaling.46
The results of this study show, for the ﬁrst time, the
importance of considering natural gene-expression vari-
ation in the context of aneuploidies and provide a frame-
work for gene classiﬁcation.We propose to prioritize genes
according to the degree of overlap in the distribution of
expression levels between trisomic and control samples;
genes in group A are most likely associated with constant
DS phenotypes, and genes in group B with variable DS
features.
Although D values were consistent across cell types for
a majority of genes, performance of a similar analysis of
well-matched human tissue collections would be highly
informative. However, there are limitations precluding
such studies with human samples. Mouse models of aneu-
ploidy, both for inbred and outbred populations, could be
used to perform detailed analyses in a wide variety of tis-
sues and developmental stages. One potential drawback
of this approach is that the gene-expression variation,
much of which is genetically determined,may be different
between human and mouse; thus, results obtained from
mouse samples will not be necessarily applicable to hu-
man trisomy 21.
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